Every November 14, World Diabetes Day is celebrated, an initiative driven by the International Diabetes Federation (IDF) and the World Health Organization (WHO). According to the organization, over 580 million people worldwide are living with diabetes, with 35 million in Latin America and the Caribbean. This number is projected to rise to 52 million by 2050, urging a transformation in care paradigms and access to innovative therapies. This year, the focus is on the well-being of people living with diabetes and the importance of building inclusive, supportive, and stigma-free work environments. In Panama, the 2025 IDF Diabetes Atlas records that the prevalence of diabetes among adults (20-79 years) is 10.7%. One of the most highlighted aspects of the new 2025 Global Clinical Guidelines on diabetes, developed by the International Diabetes Federation (IDF), is the paradigm shift in the disease's approach. The new guidelines recommend treating earlier, in an integrated and personalized way, to modify the course of the disease. The document states that an early approach—combining lifestyle changes, intensive metabolic control, and continuous follow-up—can prevent cardiovascular, renal, and neurological complications and even achieve remission in initial stages. The report also underscores the role of new metabolic therapies, such as GLP-1 receptor agonists and dual GLP-1/GIP therapies, which have transformed the treatment of type 2 diabetes. Therefore, the challenge is to ensure that scientific advances reach all patients, regardless of their context or resources. Alejandro Salvatierra, Medical Director of Adium Centroamérica y Caribe, highlighted: "It is these seemingly small decisions that generate great results for patient well-being, who need personalized and timely solutions." At Adium, they believe that transforming metabolic health in Latin America begins by changing the conversation about these pathologies. The disease's approach has evolved from a glucose-centric view to a comprehensive metabolic approach that seeks to positively impact patients' weight, cardiovascular health, and renal function, improving their life expectancy and quality of life. These innovative alternatives go beyond glucose control, promoting weight loss, cardiac and renal protection, and a better quality of life. With this new paradigm, diabetes care is advancing towards a more comprehensive and personalized model centered on people's well-being.
